Rifamycin derivatives effective against drug-resistant microbes
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 24, 2007
Grant Date -
Nov 24, 2005
app pub date -
Jan 12, 2005
filing date -
Jan 13, 2004
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.
First Claim
Other Claims data not available
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
- 2 Citation Count
- C07D Class
- 18.25 % this patent is cited more than
- 18 Age
